Variagenics awarded US patent for ApoE gene:
This article was originally published in Clinica
Executive Summary
Variagenics has gained a US patent covering its ApoE genotyping technology for determining the prognosis of a patient diagnosed with Parkinson's disease, multiple sclerosis, stroke and other brain diseases. The Cambridge, Massachusetts company's technique entails first determining which variant of the ApoE gene is present and then using the information to predict drug efficacy, patient outcome or disease risk.